Separately today the company said that its shareholders have approved its $1.6 billion acquisition of Digene.
Terms of Qiagen’s agreement with JCSG call for the company to distribute the new screens, known as the JCSG Core Suites I-IV. The company said these screens resulted from JCSG’s analysis of more than 500,000 high-throughput crystallization experiments.
"These new screens are the result of mining the vast database of crystallization experiments performed by the JCSG,” said Qiagen’s global business director of proteins Kai te Kaat.
JCSG is one of the Protein Structure Initiative’s Genomics Production Centers, and is funded by the National Institute for General Medical Sciences.
JCSG principal investigator Ian Wilson said the supplier agreement with Qiagen “enables the fruits of the NIH Protein Structure Initiative to become available to all structural biologists and allow them the opportunity to enhance their own individual success rates in protein crystallization."